U.S. Markets closed

Free Post Earnings Research Report: Thermo Fisher’s Quarterly Revenue Surged 22%; Adjusted EPS Advanced 16%

Stock Monitor: Fluidigm Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free earnings report on Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TMO. Thermo Fisher reported its fourth quarter and fiscal 2017 operating and financial results on January 31, 2018. The maker of scientific instrument and laboratory supplies surpassed top- and bottom-line expectations and provided guidance for FY18. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Fluidigm Corporation (NASDAQ: FLDM), which also belongs to the Healthcare sector as the Company Thermo Fisher Scientific. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Thermo Fisher Scientific most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Earnings Highlights and Summary

For the fourth quarter ended December 31, 2017, Thermo Fisher's revenue surged 22% to $6.05 billion compared to $4.95 billion in Q4 2016. The Company's reported quarter organic revenue growth was 8%, while acquisitions increased revenue by 11% and currency translation aided revenue growth by 3%. The Company's reported numbers topped analysts' estimates of $5.69 billion.

For full year (FY) 2017, Thermo Fisher's revenue advanced 14% to $20.92 billion versus $18.27 billion in FY16.

During Q4 2017, Thermo Fisher's GAAP operating income totaled $958 million, up 15.8% compared to operating income of $753 million in Q4 2016. The Company's reported quarter GAAP operating margin increased to 15.8% compared to 15.2% in the year ago corresponding quarter. Thermo Fisher's adjusted operating income grew 18% to $1.45 billion for Q4 2017, while adjusted operating margin decreased 80 basis points to 24.0% compared to 24.8% in Q4 2016.

For Q4 2017, Thermo Fisher reported GAAP net income of $528 million, or $1.30 per diluted share, versus net income of $630 million, or $1.59 per diluted share, in Q4 2016. The Company's reported quarter results included a one-time tax provision of $204 million associated with the recent enactment of tax reform legislation in the US.

Thermo Fisher's non-GAAP earnings advanced 16% to $2.79 per share compared to $2.41 per share in Q4 2016, driven by organic growth, favorable forex environment, and good performance from the Patheon acquisition, and partially offset by the $34 million onetime bonus for Thermo Fisher's non-executive collogues across the Company. Thermo Fisher's earnings beat Wall Street's estimates of $2.66 per share.

For FY17, Thermo Fisher reported GAAP net income of $2.23 billion, or $5.59 per share, versus earnings of $2.02 billion, or $5.09 per diluted share, in FY16. The Company's adjusted earnings for FY17 rose 15% to $9.49 per share versus $8.27 per share in FY16.

Thermo Fisher's Segment Results

During Q4 2017, the Life Sciences Solutions segment's revenue grew 11% to $1.58 billion compared to revenue of $1.42 billion in Q4 2016. The segment's adjusted operating margin increased to 35.6% in the reported quarter versus 32.9% in the year earlier same quarter.

For Q4 2017, the Analytical Instruments segment's revenue grew 16% to $1.41 billion compared to revenue of $1.22 billion in Q4 2016. The segment's adjusted operating margin was flat at 24.5%.

The Specialty Diagnostics segment's revenue advanced 10% to $914 million in Q4 2017 compared to revenue of $834 million in Q4 2016.The segment's adjusted operating margin was 26.5% in the reported quarter versus 27.2% in the prior year's same quarter.

During Q4 2017, the Laboratory Products and Services segment's results reflected the acquisition of Patheon in August 2017. In the reported quarter, the segment's revenue surged 43% to $2.40 billion compared to revenue of $1.68 billion in the year earlier same quarter. The Laboratory Products and Services segment's adjusted operating margin was 12.5% in Q4 2017 versus 14.0% in Q4 2016.

Cash Matters

For FY17, Thermo Fisher's cash flow from continuing operations was $4.0 billion and free cash flow was $3.5 billion. During FY17, the Company returned capital to shareholders with $750 million of share buybacks and $240 million in dividends. Thermo Fisher ended Q4 2017 with approximately $1.3 billion in cash and total debt of $21 billion, down $1 billion from the end of Q3 2017, driven by debt pay down during the reported quarter.


For FY18, Thermo Fisher is forecasting revenue in the range of $23.42 billion to $23.72 billion, reflecting 12% to 13% growth over FY17. The Company initiated adjusted EPS forecast for FY18 to be in the band of $10.68 to $10.88 per share, representing 13% to 15% growth over FY17 results.

Stock Performance Snapshot

February 13, 2018 - At Tuesday's closing bell, Thermo Fisher Scientific's stock slightly fell 0.49%, ending the trading session at $203.50.

Volume traded for the day: 1.22 million shares.

Stock performance in the last three-month – up 9.30%; previous six-month period – up 16.93%; past twelve-month period – up 30.16%; and year-to-date – up 7.17%

After yesterday's close, Thermo Fisher Scientific's market cap was at $80.59 billion.

Price to Earnings (P/E) ratio was at 36.33.

The stock has a dividend yield of 0.33%.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry. This sector was up 0.1% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors